Print

Olaparib with Cediranib or Ceralasertib for People with Advanced or Metastatic Breast Cancer and with a BRCA1 or BRCA2 Mutation

https://www.facingourrisk.org/research-clinical-trials/study/304/olaparib-with-cediranib-or-ceralasertib-for-people-with-advanced-or-metastatic-breast-cancer-and-with-a-brca1-or-brca2-mutation

Clinicaltrials.gov identifier:
NCT04090567 (https://clinicaltrials.gov/show/NCT04090567)

Treatment
This study will examine how Olaparib in combination with the drugs Cediranib or Ceralasertib works for patients with advanced breast cancer who have BRCA1 or BRCA2 genetic mutation and who were previously treated with a PARP inhibitor

Study Contact Information:

For additional information, please contact:  

Principal Investigator: Banu Arun, [email protected], 713-792-2817


About the Study

This study is for people with advanced or metastatic breast cancer, have a BRCA1 or BRCA2 genetic mutation and were previously treated with a PARP inhibitor. The study will examine how effective  Olaparib in combination with Cediranib or Ceralasertib is in reducing the size of cancer and determining the length of time patients respond well to the treatment.  

What the Study Involves

Participants are assigned to one of two groups in this study. They are followed for 30 days after completion of study treatment.

Group1

Participants will take Olaparib orally twice a day and Cediranib orally once a day on day 1 to day 28. They will continue with the cycles until the treatment stops working or causes serious side effects.

Group2

Participants will take Olaparib orally twice a day on day 1 to day 28 and Ceralasertib orally once a day on day 1 to day 7. They will continue with cycles until the treatment stops working or causes serious side effects.

Study Site

Texas

MD Anderson Cancer Center
Houston, Texas 77030


This Study is Open To:

Assigned female at birth aged 18 years and older, who meet the following criteria:

All groups

Group1

This Study is Not Open To:

People under 18 years old and who:


About FORCE

FORCE is a national nonprofit organization, established in 1999. Our mission is to improve the lives of individuals and families affected by adult hereditary cancers.